ACP-319

Acerta Pharma BV · Phase 1 active Small molecule

At a glance

Generic name	ACP-319
Sponsor	Acerta Pharma BV
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Acalabrutinib (ACP-196) in Combination With ACP-319, for Treatment of B-Cell Malignancies (PHASE1, PHASE2)
Acalabrutinib in Combination With ACP-319, for Treatment of Chronic Lymphocytic Leukemia (PHASE1)
Patient-Derived Xenografts in Personalizing Treatment for Patients With Relapsed/Refractory Mantle Cell Lymphoma (EARLY_PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

ACP-319 CI brief — competitive landscape report
ACP-319 updates RSS · CI watch RSS
Acerta Pharma BV portfolio CI